GZC8072

GZC8072 is an investigational oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Gan & Lee Pharmaceuticals. It is specifically designed for the treatment of obesity and overweight. Unlike traditional GLP-1 therapies that are peptide-based and often require subcutaneous injection, GZC8072 is a non-peptide small molecule formulated as a tablet, aiming to provide improved patient convenience and compliance. The drug works by selectively activating the GLP-1 receptor, which regulates glucose metabolism and appetite. GZC8072 is currently in Phase 1 clinical development, with studies evaluating its safety, tolerability, and pharmacokinetic profile in healthy volunteers and individuals with obesity or overweight.